Suven Pharma announced 53.84% growth in total revenues for the Q3FY21 on a consolidated basis at Rs274.93cr. The company’s core operation of contract development and manufacturing operations or CDMO saw good traction during the Dec-20 quarter as the global demand for CDMO was up sharply benefiting Suven in top-line growth. The consolidated PAT for the Q3FY21 was up 96.22% at Rs113.63cr.